CEVA heads into its August 12 earnings report battered and heavily shorted — a combination that makes the print unusually consequential.
The stock closed at $30.83 on Tuesday, down 32% over the past month and 15% in the past week alone. That kind of compression leaves bulls scrambling for a floor and short sellers sitting on gains. Short interest has climbed to 8.4% of the free float — meaningful for a small semiconductor IP licensor — and has risen roughly 8% over the past month as the stock declined. Despite the growing short position, the borrow market remains loose: availability is running near 907% relative to shares on loan, with borrowing costs at just 0.48%. There is no squeeze pressure in the lending pool; this is directional short selling, not a crowded trade in distress.
Options traders, by contrast, are not positioned for further downside. The put/call ratio has actually drifted well below its 20-day average — the current reading of 0.42 is nearly two standard deviations lighter on puts than normal. That divergence is notable: shorts are adding exposure while options flow leans toward calls. The setup is less a consensus bearish pile-on than a split between two different communities expressing opposite views.
Analyst activity in the 48 hours before the print has been almost uniformly negative on price. TD Cowen and Needham both slashed targets from $55 to $45 and $43 respectively, keeping Buy ratings intact. Oppenheimer trimmed to $38 from $42, also holding Outperform. Only Rosenblatt bucked the trend, raising its target to $49. The consensus mean now sits at $47.25 — still 53% above the current price — which signals that the Street believes the selloff is overdone, but is unwilling to fight it aggressively. The bull case centres on CEVA's position in smart-edge device IP, wireless connectivity exposure, and potential long-term tailwinds from physical AI workloads. Bears point to the company's structural dependence on semiconductor OEM licensing cycles, intense IP competition, and the reality that royalty revenue remains tied to a highly cyclical industry.
The institutional base adds a wrinkle worth noting. BlackRock added 209,000 shares as recently as July 31, and State Street bought 430,000 shares in the same window — meaningful accumulation from passive-to-active managers even as the stock was falling. Vanguard Capital Management initiated a full new position. On the other side, Point72 trimmed by 55,000 shares in Q1. Insider activity is less current — the most recent cluster of executive sales came in May and June at prices well above current levels ($36–$46), meaning those sellers locked in gains that have since been erased. The CEO and CFO were buyers back in February at around $19–$20, a level the stock has now fallen back toward.
One past earnings reaction stands out as context: the most recent prior-quarter print triggered a 20% single-day decline. That reaction, combined with a 12% gain two quarters ago that reversed into a 3.7% five-day loss, frames a stock that moves sharply on results and rarely holds its initial reaction. The print will test whether CEVA's royalty revenue trajectory and licensing pipeline can justify any premium above its near-decade valuation lows — or whether the selloff has already priced in a disappointment that the numbers then confirm.
See the live data behind this article on ORTEX.
Open CEVA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
